C4 Therapeutics, Inc. Operating Income Loss

• C4 Therapeutics, Inc. showed an increase of +3.7% in Operating Income Loss from 2024 to 2025.
• This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), C4 Therapeutics, Inc.'s Operating Income Loss has declined by 225.0%.
• Historical annual values: Fiscal year 2025: -$115.22 million | Fiscal year 2024: -$119.61 million | Fiscal year 2023: -$139.03 million | Fiscal year 2022: -$129.53 million | Fiscal year 2021: -$82.13 million | Fiscal year 2020: -$60.45 million | Fiscal year 2019: -$35.45 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026